Sepsis is a frequent condition, defined as life-threatening organ dysfunction associated with a severe infection.¹ Over the past three decades, progress in understanding of the pathophysiology of sepsis has led to the development of a large number of potential new therapies for sepsis. Many of these underwent preclinical testing with promising results and moved into clinical trials with the hope that they would improve survival from sepsis. Some of these interventions successfully passed early phase trials and underwent testing in large multicentre randomised controlled trials.

中文翻译：

---

重点进行临床试验研究：对败血症的试验进行反思

败血症是一种常见病，被定义为与严重感染相关的威胁生命的器官功能障碍。¹在过去的三十年中，对脓毒症的病理生理学的了解不断发展，导致开发出了许多潜在的脓毒症新疗法。其中许多经过了临床前测试，并获得了可喜的结果，并进入临床试验，希望它们可以改善败血症的存活率。其中一些干预措施成功通过了早期试验，并在大型多中心随机对照试验中进行了测试。